Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.
Recent evidence suggest the implication of transition metals leading to overproduction of free radicals as a possible causal factor in the death of nigral cells associated to Parkinson's disease (PD). Iron depots in the basal ganglia of PD patients have been described; in addition, contents of nigral copper have been found decreased, while its concentration in cerebrospinal fluid (CSF) is raised, particularly the free form of the metal. To search for a possible link between altered copper concentrations and PD, we advanced the hypothesis that ferroxidase activity of ceruloplasmin is decreased in the CSF of PD patients. We studied 35 untreated PD patients, 14 L-3,4-dihydroxyphenylalanine (L-DOPA)-treated PD patients and 26 controls. Both CSF ferroxidase activity and CSF copper content were measured and correlated with the clinical stage of the disease. We found that untreated PD patients had a significant reduction of 40% in CSF ferroxidase while CSF copper was slightly increased as compared with both the values in L-DOPA-treated PD patients and controls. We also found that the fraction of copper linked to ferroxidase in untreated PD is inversely related to the clinical stage of the disease.
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage; D002570:Ceruloplasmin / Q000134:cerebrospinal fluid* / Q000378:metabolism; D003300:Copper / Q000378:metabolism; D004789:Enzyme Activation / Q000502:physiology; D005260:Female; D006801:Humans; D007501:Iron / Q000378:metabolism; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000201:enzymology*